Prostate Cancer Clinical Trials in Salt Lake City

Showing 61-80 of 261 trials

Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

NCT05534646

This is an open-label, multi-site study of apalutamide with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy. This study will begin with a safety assessment in the first 10 subjects (part 1: Safety Lead-in). If the combination is deemed safe, the trial will proceed to the Phase II stage. The purpose of this study is to compare progression free survival (PFS) between patients receiving apalutamide and apalutamide + carotuximab using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3. The secondary objectives are to describe adverse events related to the intervention, overall response rate (ORR), proportion of patients resistant to apalutamide that benefit from the addition of carotuximab, and to determine the ORR, radiographic PFS, and biochemical PFS in the overall population.

Castration-resistant Prostate Cancer

Edwin Posadas, MD100 participantsStarted Dec 2023

Duarte, California, United States • Los Angeles, California, United States • Salt Lake City, Utah, United States

TERMINATEDPhase 2< 1 mile

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

NCT01995058

This study was conducted in subjects in chemotherapy-naïve subjects with bone-metastatic castration-resistant prostate cancer (CRPC).

Prostate CancerCastration Resistant Prostate CancerProstatic Neoplasms

Exelixis54 participantsStarted Feb 2014

Scottsdale, Arizona, United States • Sedona, Arizona, United States • Tucson, Arizona, United States +17 more locations

Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Prostate Cancer Trials in Other Cities

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Massage for Prostate Cancer-Related Fatigue (mPROSTATE)

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Evaluation of Neuroendocrine Differentiation as a Potential Mechanism of Tumor Recurrence Following Radiotherapy

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

Other Conditions in Salt Lake City